Title

Intraoperative Lidocaine Infusion for Postoperative Pain Management in Obese Patients
Systemic Intraoperative Lidocaine Infusion for Postoperative Pain Management in Obese Patients: A Randomized, Placebo-Controlled Pilot Study
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Intervention/Treatment

    lidocaine ...
  • Study Participants

    20
The primary objective is to assess the feasibility and safety of administering continuous intraoperative lidocaine infusions in adult patients undergoing laparoscopic Roux en Y Gastric Bypass (RYGB). The secondary objective is to determine if lidocaine administration versus placebo (dextrose administration) (initiated at the time of anesthesia induction and continued until extubation) will reduce postoperative narcotic requirements.
Study Started
Aug 31
2013
Primary Completion
Jul 31
2014
Study Completion
Sep 30
2014
Results Posted
Oct 26
2017
Last Update
Oct 26
2017

Drug Lidocaine

Drug Placebo

Lidocaine Experimental

Intraoperative continuous IV infusion of Lidocaine at 2mg/kg/hr

Placebo Active Comparator

Intraoperative continuous placebo infusion of dextrose at 2mg/kg/hr

Criteria

Inclusion Criteria:

Adult patients between the ages of 18-65 years old
BMI ≥ 40 kg/m2, ≤ 60 kg/m2
Undergoing a primary laparoscopic RYGB by Dr. Murr
Agree to be followed 24 hours postoperatively
Normal K+ and Mg++ serum levels

Exclusion Criteria:

BMI less than 40 kg/m2, > 60 kg/m2
Laparoscopic RYGB surgery performed by a surgeon other than Dr. Murr
Allergy to lidocaine
Allergy to hydromorphone or ketorolac
Allergy to corn or amide anesthetics
Use of (thioridizine)
Pregnancy
Abnormalities of ALT or AST
Intra-operative diagnosis of cirrhosis or portal hypertension
Intraoperative complications per surgeon
Intraoperative extensive adhesions per surgeon
Chronic pain syndrome and chronic use of narcotics
Severe back pain secondary to degenerative joint disease

Summary

Lidocaine

Placebo

All Events

Event Type Organ System Event Term Lidocaine Placebo

Postoperative Pain

Analysis of patient outcome will involve a series of visual analogue scale (VAS, 0 cm as no pain - 10 cm as maximum pain) pain evaluations during mobilization, coughing, and resting

Lidocaine

Coughing VAS

6.0
units on a scale (Median)
Full Range: 2.0 to 10.0

Moving VAS

6.0
units on a scale (Median)
Full Range: 4.0 to 9.0

Resting VAS

2.5
units on a scale (Median)
Full Range: 0.0 to 9.0

Placebo

Coughing VAS

6.5
units on a scale (Median)
Full Range: 4.0 to 9.0

Moving VAS

7.0
units on a scale (Median)
Full Range: 4.0 to 8.0

Resting VAS

4.5
units on a scale (Median)
Full Range: 0.0 to 8.0

Postoperative Pain

Analysis of patient outcome will involve a series of visual analogue scale pain evaluations during mobilization, coughing, and resting. VAS, 0 cm as no pain - 10 cm as maximum pain

Lidocaine

Coughing VAS

8.0
units on a scale (Median)
Full Range: 2.0 to 10.0

Moving VAS

6.0
units on a scale (Median)
Full Range: 2.0 to 10.0

Resting VAS

3.0
units on a scale (Median)
Full Range: 0.0 to 8.0

Placebo

Coughing VAS

5.5
units on a scale (Median)
Full Range: 4.0 to 10.0

Moving VAS

4.5
units on a scale (Median)
Full Range: 4.0 to 10.0

Resting VAS

3.5
units on a scale (Median)
Full Range: 0.0 to 10.0

Postoperative Pain

Analysis of patient outcome will involve a series of visual analogue scale pain evaluations during mobilization, coughing, and resting. VAS, 0 cm as no pain - 10 cm as maximum pain

Lidocaine

Coughing VAS

8.0
units on a scale (Median)
Full Range: 3.0 to 10.0

Moving VAS

8.0
units on a scale (Median)
Full Range: 0.0 to 10.0

Resting VAS

3.0
units on a scale (Median)
Full Range: 0.0 to 10.0

Placebo

Coughing VAS

8.0
units on a scale (Median)
Full Range: 5.0 to 9.0

Moving VAS

8.0
units on a scale (Median)
Full Range: 4.0 to 9.0

Resting VAS

4.5
units on a scale (Median)
Full Range: 0.0 to 8.0

Postoperative Pain

Analysis of patient outcome will involve a series of visual analogue scale (VAS, 0 cm as no pain - 10 cm as maximum pain) pain evaluations during mobilization, coughing, and resting

Lidocaine

Coughing VAS

7.0
units on a scale (Median)
Full Range: 5.0 to 10.0

Moving VAS

8.0
units on a scale (Median)
Full Range: 5.0 to 10.0

Resting VAS

3.5
units on a scale (Median)
Full Range: 0.0 to 9.0

Placebo

Coughing VAS

7.0
units on a scale (Median)
Full Range: 2.0 to 9.0

Moving VAS

7.0
units on a scale (Median)
Full Range: 5.0 to 8.0

Resting VAS

4.0
units on a scale (Median)
Full Range: 0.0 to 6.0

Total

20
Participants

BMI

47.5
kg/m^2 (Mean)
Standard Deviation: 5.9

Age, Continuous

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Region of Enrollment

Sex: Female, Male

Overall Study

Lidocaine

Placebo

Drop/Withdrawal Reasons

Lidocaine